<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Oncohematology</journal-id><journal-title-group><journal-title xml:lang="en">Oncohematology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкогематология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1818-8346</issn><issn publication-format="electronic">2413-4023</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">519</article-id><article-id pub-id-type="doi">10.17650/1818-8346-2022-17-1-53-64</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>RARE AND COMPLEX CLINICAL SITUATIONS: DIAGNOSTIC DIFFICULTIE AND TREATMENT CHOICE</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>РЕДКИЕ И СЛОЖНЫЕ КЛИНИЧЕСКИЕ СИТУАЦИИ: ТРУДНОСТИ ДИАГНОСТИКИ И ВЫБОР ТАКТИКИ ЛЕЧЕНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Rare variants of histiocytic tumors: peculiarities of diagnosis and choice of treatment (literature review)</article-title><trans-title-group xml:lang="ru"><trans-title>Редкие варианты гистиоцитарных опухолей: особенности диагностики и выбора тактики лечения (обзор литературы)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1469-2365</contrib-id><name-alternatives><name xml:lang="en"><surname>Valiev</surname><given-names>T. T.</given-names></name><name xml:lang="ru"><surname>Валиев</surname><given-names>Т. Т.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115478</italic>,</p><p><italic>8 Trubetskaya St., Moscow 119991</italic></p></bio><bio xml:lang="ru"><p><italic>115478 Москва, Каширское шоссе, 24</italic>,</p><p><italic>119991 Москва, ул. Трубецкая, 8 </italic></p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0050-0721</contrib-id><name-alternatives><name xml:lang="en"><surname>Gurieva</surname><given-names>O. D.</given-names></name><name xml:lang="ru"><surname>Гурьева</surname><given-names>О. Д.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><bold>Oksana D</bold><bold>.</bold><bold> Gurieva</bold></p><p><italic>24 Kashirskoe Shosse, Moscow 115478</italic></p></bio><bio xml:lang="ru"><p><bold>Оксана Дмитриевна Гурьева</bold></p><p><italic>115478 Москва, Каширское шоссе, 24</italic></p></bio><email>swimmer96ok@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6300-0062</contrib-id><name-alternatives><name xml:lang="en"><surname>Pavlovskaya</surname><given-names>A. I.</given-names></name><name xml:lang="ru"><surname>Павловская</surname><given-names>А. И.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p><italic>24 Kashirskoe Shosse, Moscow 115478</italic></p></bio><bio xml:lang="ru"><p><italic>115478 Москва, Каширское шоссе, 24</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский Университет)</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-01-29" publication-format="electronic"><day>29</day><month>01</month><year>2022</year></pub-date><volume>17</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>53</fpage><lpage>64</lpage><history><date date-type="received" iso-8601-date="2022-01-29"><day>29</day><month>01</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-01-29"><day>29</day><month>01</month><year>2022</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncohematology.abvpress.ru/ongm/article/view/519">https://oncohematology.abvpress.ru/ongm/article/view/519</self-uri><abstract xml:lang="en"><p>Histiocytic tumors are a highly heterogeneous group of diseases, with Langerhans cell histiocytosis occupying the main place among it. Despite the rare frequency of occurrence, long-term analysis of clinical, morpho-immunological and molecular-biological features has allowed the development of effective treatment protocols (especially in the pediatric cohort of patients). In addition to Langerhans cell histiocytosis, the histiocytic tumors group includes rare and casuistic variants, which include histiocytic sarcoma, Langerhans cell sarcoma, indeterminate dendritic cell tumor, interdigitating dendritic cell sarcoma, follicular dendritic cell sarcoma, and fibroblastic reticular cell tumor. The incidence of certain nosological variants is several cases per hundreds of millions of the population. Not surprisingly, the diagnostic criteria for this group of tumors need to be clarified, as do the therapeutic approaches. This review presents current data on rare histiocytic tumors, clinical features as well as morphological and immunobiological characteristics of the tumor substrate. The results of modern surgical and therapeutic treatment approaches are presented.</p></abstract><trans-abstract xml:lang="ru"><p>Гистиоцитарные опухоли являются весьма гетерогенной группой, основное место среди них занимает гистиоцитоз из клеток Лангерганса. Несмотря на редкую встречаемость, многолетний анализ клинических, морфоиммунологических и молекулярно-биологических особенностей позволил разработать эффективные протоколы лечения, особенно в детской когорте больных. Помимо гистиоцитоза из клеток Лангерганса в группу гистиоцитарных опухолей входят редкие и казуистические варианты, к которым относятся гистиоцитарная саркома, саркома из клеток Лангерганса, опухоль из дендритических клеток неуточненная, саркома из интердигитирующих дендритных клеток, фолликулярная дендритноклеточная саркома, фибробластическая опухоль из ретикулярных клеток. Частота отдельных нозологических вариантов составляет несколько случаев на сотни миллионов населения. Неудивительно, что диагностические критерии для данной группы опухолей нуждаются в уточнении, равно как и терапевтические подходы. В настоящем обзоре приведены современные данные о редких гистиоцитарных опухолях, представлены клинические особенности, а также морфологические и иммунобиологические характеристики опухолевого субстрата. Приведены результаты использования современного арсенала хирургических и терапевтических подходов к лечению.</p></trans-abstract><kwd-group xml:lang="en"><kwd>histiocytic sarcoma</kwd><kwd>Langerhans cell sarcoma</kwd><kwd>indeterminate dendritic cell tumor</kwd><kwd>interdigitating dendritic cell sarcoma</kwd><kwd>follicular dendritic cell sarcoma</kwd><kwd>fibroblastic reticular cell tumor</kwd><kwd>clinical picture</kwd><kwd>diagnosis</kwd><kwd>treatment</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>гистиоцитарная саркома</kwd><kwd>саркома из клеток Лангерганса</kwd><kwd>опухоль из дендритических клеток неуточненная</kwd><kwd>саркома из интердигитирующих дендритных клеток</kwd><kwd>фолликулярная дендритноклеточная саркома</kwd><kwd>фибробластическая опухоль из ретикулярных клеток</kwd><kwd>клиническая картина</kwd><kwd>диагностика</kwd><kwd>лечение</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Tang X., Gao J., Ma Z.G. et al. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020. Ann Med 2021;53(1):1537–46. DOI: 10.1080/07853890.2021.1966085.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edn.). Eds.: S.H. Swerdlow, E. Campo, N.L. Harris et al. Lyon: IARC, 2017. 470 p.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Kommalapati A., Tella S.H., Durkin M. et al. Histiocytic sarcoma: a populationbased analysis of incidence, demographic disparities, and long-term outcomes. Blood 2018;131(2):265–8. DOI: 10.1182/blood-2017-10-812495.</mixed-citation></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Doronin V.A., Krivolapov Yu.A., Nechesnyuk A.V., Pivnik A.V. Histiocytic sarcoma. A clinical case and review of the literature. Klinicheskaya onkogematologiya. Fundamental’nye issledovaniya i klinicheskaya praktika = Clinical Oncohematology. Fundamental Research and Clinical Practice 2009;2(2):161–6. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Доронин В.А., Криволапов Ю.А., Нечеснюк А.В., Пивник А.В. Гистиоцитарная саркома. Клинический случай и обзор литературы. Клиническая онкогематология. Фундаментальные исследования и клиническая практика 2009;2(2):161–6.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><mixed-citation>Feldman A.L., Arber D.A., Pittaluga S. et al. Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone. Blood 2008;111(12):5433–9. DOI: 10.1182/blood-2007-11-124792.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Milutinovic S., Abe J., Godkin A. et al. The dual role of high endothelial venules in cancer progression versus immunity. Trends Cancer 2021;7(3):214–25. DOI: 10.1016/j.trecan.2020.10.001.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Chen W., Lau S.K., Fong D. et al. High frequency of clonal immunoglobulin receptor gene rearrangements in sporadic histiocytic/dendritic cell sarcomas. Am J Surg Pathol 2009;33(6):863–73. DOI: 10.1097/PAS.0b013e31819287b8.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Gounder M.M., Solit D.B., Tap W.D. Trametinib in histiocytic sarcoma with an activating MAP2K1 (MEK1) mutation. N Engl J Med 2018;378(20):1945–7. DOI: 10.1056/NEJMc1511490.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Shanmugam V., Griffin G.K., Jacobsen E.D. et al. Identification of diverse activating mutations of the RAS-MAPK pathway in histiocytic sarcoma. Mod Pathol 2019;32(6):830–43. DOI: 10.1038/s41379-018-0200-x.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Hornick J.L., Jaffe E.S., Fletcher C.D. Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol 2004;28(9):1133–44. DOI: 10.1097/01.pas.0000131541.95394.23.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Chen D.B. Langerhans cell sarcoma. Atlas Genet Cytogenet Oncol Haematol 2020;24(10):369–72. DOI: 10.4267/2042/70818.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Karai L.J., Sanik E., Ricotti C.A. et al. Langerhans cell sarcoma with lineage infidelity/plasticity: a diagnostic challenge and insight into the pathobiology of the disease. Am J Dermatopathol 2015;37(11):854–61. DOI: 10.1097/DAD.000000000000031.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Nakamine H., Yamakawa M., Yoshino T. et al. langerhans cell histiocytosis and langerhans cell sarcoma: current understanding and differential diagnosis. J Clin Exp Hematop 2016;56(2):109–18. DOI: 10.3960/jslrt.56.109.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Matsukawa T., Suto K., Miyoshi H. et al. Successful treatment of an elderly Langerhans cell sarcoma patient by EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) chemotherapy. J Clin Exp Hematop 2018;58(4):184–7. DOI: 10.3960/jslrt.18027.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Zwerdling T., Won E., Shane L. et al. Langerhans cell sarcoma: case report and review of world literature. J Pediatr Hematol Oncol 2014;36(6):419–25. DOI: 10.1097/MPH.0000000000000196.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Howard J.E.F., Dwivedi R.C., Masterson L., Jani P. Langerhans cell sarcoma: a systematic review. Cancer Treat Rev 2015;41(4):320–31. DOI: 10.1016/j.ctrv.2015.02.011.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Brown R.A., Kwong B.Y., McCalmont T.H. et al. ETV3-NCOA2 in indeterminate cell histiocytosis: clonal translocation supports sui generis. Blood 2015;126(20):2344–5. DOI: 10.1182/blood-2015-07-655530.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Wood G.S., Garcia C.F., Dorfman R.F. et al. The immunohistology of follicle lysis in lymph node biopsies from homosexual men. Blood 1985;66(5):1092–7.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Pokuri V.K., Merzianu M., Gandhi S. et al. Interdigitating dendritic cell sarcoma. J Natl Compr Canc Netw 2015;13(2):128–32. DOI: 10.6004/jnccn.2015.0020.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Diego C.R., Luis M., Samir D. Indeterminate dendritic cell tumor. Atlas Genet Cytogenet Oncol Haematol 2019;23(11): 342–44. DOI: 10.4267/2042/70612.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Diego C.R., Luis M., Samir D. Interdigitating Dendritic Cell Sarcoma. Atlas Genet Cytogenet Oncol Haematol 2019;23(10):317–19. DOI: 10.4267/2042/70582</mixed-citation></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Zeynalova P.A., Pavlovskaya A.I., Valiev T.T. et al. Sarcoma from interdigitating dendritic cells: clinical observation and literature data. Klinicheskaya onkogematologiya. Fundamental’nye issledovaniya i klinicheskaya praktika = Clinical Oncohematology. Fundamental Research and Clinical Practice 2013;6(3):318–23. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Зейналова П.А., Павловская А.И., Валиев Т.Т. и др. Саркома из интердигитирующих дендритных клеток: клиническое наблюдение и данные литературы. Клиническая онкогематология. Фундаментальные исследования и клиническая практика 2013;6(3):318–23.</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><mixed-citation>Jiang X.N., Zhang Y., Xue T. et al. New clinicopathologic scenarios of EBV+ inflammatory follicular dendritic cell sarcoma: report of 9 extrahepatosplenic cases. Am J Surg Pathol 2021;45(6):765–72. DOI: 10.1097/PAS.0000000000001632.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Sasaki M., Izumi H., Yokoyama T. et al. Follicular dendritic cell sarcoma treated with a variety of chemotherapy. Hematol Oncol 2017;35(4):905–8. DOI: 10.1002/hon.2364.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Diego C.R., Luis M., Samir D. Fibroblastic reticular cell tumor. Atlas Genet Cytogenet Oncol Haematol 2020;24(3):140–1. DOI: 10.4267/2042/70680.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Goto N., Tsurumi H., Takami T. et al. Cytokeratin-positive fibroblastic reticular cell tumor with follicular dendritic cell features: a case report and review of the literature. Am J Surg Pathol 2015;39(4):573–80. DOI: 10.1097/PAS.0000000000000362.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Martel M., Sarli D., Colecchia M. et al. Fibroblastic reticular cell tumor of the spleen: report of a case and review of the entity. Hum Pathol 2003;34(9):954–7. DOI: 10.1016/S0046-8177(03)00399-X.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>The Hospital for Sick Children. International Rare Histiocytic Disorders Registry (IRHDR). In: ClinicalTrials.gov [Internet] (cited 2021 November 05). NLM Identifier: NCT02285582. Available at: https://clinicaltrials.gov/ct2/show/record/NCT02285582?view=record.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Emile J.F., Abla O., Fraitag S. et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016;127(22):2672–81. DOI: 10.1182/blood-2016-01-690636.</mixed-citation></ref></ref-list></back></article>
